TITANBIO

Titan Bio-Tech share price & financials

Price
₹427.95
Market cap
₹1.9k Cr

Quarterly results

Q1 FY27: revenue up 28.3%, net profit up 57.1% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue40 38 35 46 54 +35%57 +50%49 +40%59 +28%
EBITDA8 5 5 9 9 +13%11 +120%10 +100%12 +33%
Net profit7 4 4 7 8 +14%9 +125%7 +75%11 +57%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance +209.1% 1Y

₹200₹300₹400₹500Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹141.63 on 10 Sept 2025 → ₹437.8. High ₹529.2 (6 Apr 2026), low ₹141.63 (10 Sept 2025).

Financials, as filed

Revenue grew 12.1% a year over 2 years, FY24 to FY26. Operating margin narrowed to 18.9%.

Year endingFY24FY25FY26
Revenue₹164 Cr₹156 Cr₹206 Cr
Operating profit₹35 Cr₹26 Cr₹39 Cr
Operating margin21.3%16.7%18.9%
Interest₹0 Cr₹0 Cr₹0 Cr
Depreciation₹4 Cr₹4 Cr₹4 Cr
Net profit₹25 Cr₹21 Cr₹31 Cr
Net margin15.2%13.5%15.0%
Cash from operations₹21 Cr₹20 Cr₹30 Cr
Free cash flow₹12 Cr₹12 Cr₹21 Cr
ROCE25.0%17.0%23.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹8 Cr₹8 Cr₹8 Cr₹8 Cr₹8 Cr₹8 Cr
Reserves₹60 Cr₹78 Cr₹102 Cr₹125 Cr₹158 Cr₹173 Cr
Borrowings₹16 Cr₹9 Cr₹9 Cr₹8 Cr₹9 Cr₹6 Cr
Other liabilities₹16 Cr₹13 Cr₹16 Cr₹15 Cr₹27 Cr₹27 Cr
Total liabilities₹101 Cr₹108 Cr₹135 Cr₹157 Cr₹202 Cr₹214 Cr
Fixed assets₹34 Cr₹35 Cr₹36 Cr₹52 Cr₹57 Cr₹62 Cr
Capital work in progress₹0 Cr₹4 Cr₹13 Cr₹3 Cr₹4 Cr₹2 Cr
Investments₹0 Cr₹4 Cr₹15 Cr₹28 Cr₹48 Cr₹60 Cr
Other assets₹67 Cr₹65 Cr₹70 Cr₹74 Cr₹95 Cr₹90 Cr
Total assets₹101 Cr₹108 Cr₹135 Cr₹157 Cr₹202 Cr₹214 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, the public added +0.11 pp. The shareholder count grew 14% to 18,671.

Promoters
55.8%
DIIs
0.0%
Public
44.2%

Since Jun 2025

  • Public +0.11 pp
  • Promoters −0.09 pp
  • DIIs −0.02 pp

How it drifted, 12 quarters

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 55.9%, Public 44.1%.Dec '23: Promoters 55.9%, Public 44.1%.Mar '24: Promoters 55.9%, DIIs 0.2%, Public 43.9%.Jun '24: Promoters 55.9%, Public 44.1%.Sep '24: Promoters 55.9%, Public 44.1%.Dec '24: Promoters 55.9%, Public 44.1%.Mar '25: Promoters 55.9%, DIIs 0.0%, Public 44.1%.Jun '25: Promoters 55.9%, DIIs 0.0%, Public 44.1%.Sep '25: Promoters 55.8%, DIIs 0.0%, Public 44.2%.Dec '25: Promoters 55.8%, DIIs 0.0%, Public 44.2%.Mar '26: Promoters 55.8%, DIIs 0.0%, Public 44.2%.Jun '26: Promoters 55.8%, DIIs 0.0%, Public 44.2%.

Who was buying across the market this quarter →

Who is on the register

Named in the Jun 2026 filing

Every holder of Titan Bio-Tech Ltd. above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Titan Securities Ltd 33.59%unchanged
Investor Education And Protection Fund Authority 9.51%−0.07 pp
Tanita Leasing & Finance Limited 9.49%unchanged
Connoisseur Management Services Private Limit 6.78%unchanged
Manish Goel 2.80%unchanged
Titan Biotech Limited Unclaimed Suspense Dema 2.36%−0.15 pp
Suresh Chand Singla 1.28%unchanged
Manju Singla 0.86%unchanged
Madhu Gupta 0.80%unchanged
Raja Singla 0.74%unchanged
Supriya Singla 0.66%unchanged
Udit Singla 0.61%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Learn to analyse Titan Bio-Tech Ltd.

Guides on how to read this kind of business and the numbers that matter.